pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

130 catalysts · 37 phase 2 completion · 26 phase 1 completion · 21 phase 1 2 completion · 15 phase 1 initiation · 9 phase 1 2 initiation · 8 phase 0 trial completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 26 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: lupus×TA: pulmonology×TA: cardiology×TA: oncology×clear all
type
  • phase 2 completion37
  • phase 1 completion26
  • phase 1 2 completion21
  • phase 1 initiation15
  • phase 1 2 initiation9
  • phase 0 trial completion8
  • phase 2 initiation4
  • phase 3 initiation3
  • fda advisory committee meeting2
  • phase iv trial initiation1
  • therapy area
    • Oncology98
    • Cardiology26
    • Immunology17
    • Infectious Disease16
    • Dermatology13
    • Pulmonology11
    • Ophthalmology10
    • Women's Health9
    • Pain7

    Week of Apr 27, 2026

    50
    ›Apr 29, 2026phase 0 trial completion91d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion91d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion91d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 initiation91d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation91d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion91d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion91d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 initiation91d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation91d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation91d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation91d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 2 results91d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 3 completion91d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation91d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation91d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase 3 initiation91d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 29, 2026phase iv trial initiation91d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe90d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting90d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting90d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

    Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

    full page →dantrolene →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion90d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

    full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata
    ›Apr 30, 2026phase 0 trial initiation90d agoWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Brain Tumor

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoChugai Pharmaceutical Co Ltd — tocilizumab (Phase I Trial Completion)tocilizumab

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma

    full page →tocilizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoNational Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)Anti-CD19/CD20/CD22 CAR T-cells

    Therapy area: Oncology. Indication: Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), B-Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Lymphoma, Non-Hodgkin Lymphoma, Unspecified B-Cell Lymphomas

    full page →Anti-CD19/CD20/CD22 CAR T-cells →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoEOC Pharma Ltd — EOC-237 (Phase I Trial Completion)EOC-237

    Therapy area: Oncology. Indication: Solid Tumor

    full page →EOC-237 →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoJiangxi Jemincare Group Co Ltd — JMKX-003142 (Phase I Trial Completion)JMKX-003142

    Therapy area: Cardiovascular, Genetic Disorders. Indication: Edema, Polycystic Kidney Disease

    full page →JMKX-003142 →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoChangzhou Hengbang Pharmaceutical Co Ltd — risvutatug rezetecan (Phase I Trial Completion)risvutatug rezetecan

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →risvutatug rezetecan →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →pneumococcal (20-valent) vaccine →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoJiangsu Postgraduate Research and Practice Innovation Program — acetaminophen (Phase I Trial Completion)acetaminophen ER

    Therapy area: Cardiovascular. Indication: Patent Ductus Arteriosus

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoNational Cancer Institute US — tuvusertib (Phase I Trial Completion)tuvusertib

    Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer

    full page →tuvusertib →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoPhrae Hospital — bupivacaine (Phase I Trial Completion)bupivacaine

    Therapy area: Cardiovascular, Central Nervous System, Gastrointestinal. Indication: Hypotension, Post Operative Nausea And Vomiting, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)cabozantinib s-malate

    Therapy area: Oncology. Indication: Solid Tumor

    full page →cabozantinib s-malate →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoCellenkos Inc — CK-0804 (Phase I Trial Completion)CK-0804

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)

    full page →CK-0804 →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoBeOne Medicines AG — BG-89894 (Phase I Trial Completion)BG-89894

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor

    full page →BG-89894 →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoAngel Pharmaceuticals Inc — soquelitinib (Phase I Trial Completion)soquelitinib

    Therapy area: Oncology. Indication: Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), T-Cell Leukemia, T-Cell Lymphomas

    full page →soquelitinib →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoKyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)brentuximab vedotin

    Therapy area: Oncology. Indication: Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

    full page →brentuximab vedotin →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoShanghai Institute of Biological Products Co Ltd — SIBPA-13 (Phase I Trial Completion)SIBPA-13

    Therapy area: Oncology. Indication: Breast Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Non-Small Cell Lung Cancer, Solid Tumor

    full page →SIBPA-13 →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)stiripentol

    Therapy area: Oncology. Indication: Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer

    full page →stiripentol →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoNational Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)emavusertib hydrochloride

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    full page →emavusertib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoSiteman Cancer Center — soficabtagene geleucel (Phase I Trial Completion)soficabtagene geleucel

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sezary Syndrome, T-Cell Leukemia, T-Cell Lymphomas, Transformed Mycosis Fungoides

    full page →soficabtagene geleucel →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)daraxonrasib

    Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor

    full page →daraxonrasib →source: globaldata
    ›Apr 30, 2026phase 1 completion90d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

    Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

    full page →undisclosed Covid-19 vaccine →source: globaldata
    ← prev
    page 1 of 3
    next →
    $RVMD181.88-3.29%
    $INCY129.34+8.81%
    $AZN169.64+0.22%
    $TAK17.55+0.60%
    $CPIX6.8700-2.28%
    $AZN169.64+0.22%
    $ONC327.78+0.58%
    $AZN169.64+0.22%